News | Pulmonary Embolism | October 18, 2019

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Study finds readmitted patients twice as likely to die than patients on their first admission

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Image courtesy of the American Heart Association


October 18, 2019 —­­ Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers, according to new research presented at the CHEST Annual Meeting 2019, Oct. 19-23 in New Orleans. The research will be presented by Kam Sing Ho, M.D., from Mount Sinai St. Luke’s and Mount Sinai West in New York City. 

Pulmonary emboli (PE), or blood clots in the lung, are common and are associated with 100,000 deaths annually. Risk factors include advanced age, surgery, trauma, prolonged immobility, cancer, pregnancy, estrogen therapy, congestive heart failure and defects in blood coagulation factors.

The researchers conducted a retrospective study using the AHRQ-HCUP Nationwide Readmission Database to study the role of smoking in hospital readmissions with a primary diagnosis of PE and a secondary diagnosis of tobacco dependence, also called active smoking.

“Active smokers have a higher hospital readmission rate (34.2 percent) for pulmonary embolism,” stated Ho. “We found that 11 percent of smokers and nearly 9 percent of nonsmokers with PE were readmitted to the hospital within 30 days. The most common cause (13 percent) for readmission was PE. Smoking was an independent predictor associated with higher readmission rate.”

The investigators found that readmitted patients were twice as likely to die than patients on their first admission (6.27 percent vs. 3.16 percent). Smoking was associated with readmission as were female gender, atrial fibrillation, in-hospital oxygen requirement, Medicare insurance and additional illnesses. Private insurance and higher income status were associated with fewer readmissions.

“Previous reports have shown that smoking cessation services are underutilized within the hospital,” commented Ho. “The National Readmission Database provides a platform to identify these correlations. This is an early study with promising results, which we are planning further refine with our own hospital database. In the future, we want to incorporate smoking cessation services for all adults hospitalized with pulmonary emboli.”

Michelle Cao, M.D., member of the American College of Chest Physicians Scientific Presentations and Awards Committee and clinical associate professor at Stanford University, California, addressed the importance of smoking cessation and the next step in implementation: “This study provides an opportunity to evaluate methods of implementing tobacco cessation, in light of possible increased risk of pulmonary embolism in smokers. One of the questions posed is how can we better utilize in- hospital smoking cessation programs as well as outpatient programs. Can this service be driven by primary care providers and/or pulmonologists? Successful smoking cessation programs would have major implications on morbidity, mortality as well as economic burden.”

For more information: www.chestmeeting.chestnet.org

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now